Column: US appeals court rejects lenient test for asset freezes in SEC enforcement actions
The opinions expressed here are those of the author, a columnist for Reuters.
By Alison Frankel
July 10 (Reuters) -A U.S. appeals court has just deepened a split among the federal circuits on the proper test for asset freezes in cases brought by the U.S. Securities and Exchange Commission.
The Philadelphia-based 3rd U.S. Circuit Court of Appeals ruled on Tuesday that the SEC cannot sidestep the stringent, four-part test for obtaining a preliminary injunction when it seeks to freeze the assets of a defendant in an enforcement action.
That conclusion is at odds with precedent from the New York-based 2nd Circuit, which requires the SEC only to meet one element of the four-part test. To obtain an asset freeze in the 2nd Circuit, the SEC must simply establish an inference that a defendant violated federal securities laws.
The 3rd Circuit rejected both the limited scope and the low bar of that test in Tuesday's decision. It held not only that the SEC must prove a likelihood of succeed on the merits of its allegations -- a more stringent standard than the 2nd Circuit's "inference" requirement -- but also that trial courts must consider the three other traditional preliminary injunction factors before freezing the assets of an SEC target. (Those factors, in case you've forgotten, are irreparable harm, a balance of equities and the public interest.)
The 1st Circuit has also ruled that courts must take irreparable harm into account when the SEC moves for an asset freeze.
“We can understand why the SEC likes [the 2nd Circuit] approach, but there is no statutory basis for it,” wrote 3rd Circuit Judge Kent Jordan for a panel that also included Judges Thomas Ambro and Stephanos Bibas. “Nor can we see any other reason to hold the SEC to a lower burden when it argues for an asset freeze.”
The appeals court nevertheless held that even under the more stringent test, U.S. District Judge John Vazquez of Newark, New Jersey, acted within his discretion in freezing most of the assets of Dale Chappell, a scientist and investor whom the SEC has sued for insider trading in the New Jersey-based biopharmaceutical company Humanigen HGENQ.PK.
The 3rd Circuit concluded that the SEC was likely to succeed on the merits of its claim that Chappell, a majority shareholder of several investment funds that, in turn, control a majority of Humanigen’s shares, sold off Humanigen shares based on confidential information. The SEC claims that Chappell, who also served as Humanigen's chief science officer, avoided nearly $40 million in losses by dumping shares after learning that the U.S. government was likely to reject Humanigen’s application for emergency use of its only product, an anti-inflammatory drug.
The appeals court also found the SEC adequately alleged a risk of irreparable harm because Chappell, who has relinquished his U.S. citizenship and now lives “lavishly” (in the 3rd Circuit’s word) in Switzerland, might try to shield assets from U.S. authorities. The other two preliminary injunction factors, the appeals court said, also weigh in favor of an asset freeze. (The trial judge modified the freeze to allow for legal expenses, educational costs for Chappell’s children and $50,000 for Chappell’s wife.)
The SEC did not respond to a query on the new ruling.
Chappell counsel Marc Rosen of Kleinberg, Kaplan, Wolff & Cohen said via email that the 3rd Circuit reached the right result on the proper standard of review for SEC asset freeze requests but that he and his client are “certainly disappointed with the appellate court’s application of that standard in this case.”
Chappell told the 3rd Circuit that he acted in good faith when he heeded concerns of his funds' minority investors and sold off part of the funds' holdings in Humanigen. Chappell pointed out that he disclosed his plans to sell shares to Humanigen’s board and obtained approval for the sales from the company’s compliance team.
Chappell moreover argued that the U.S. government’s warning that it was likely to deny Humanigen’s emergency use application was not material to investors, as the board concluded when it decided not to disclose the tentative determination in SEC filings.
Chappell ultimately lost more than $100 million from his investment in Humanigen, according to his brief. Chappell counsel Rosen said his side believes the full record will prove Chappell and his funds did not trade illegally.
The 3rd Circuit’s decision is the latest example of courts refusing to grant special treatment to federal agencies. As Jordan explained in Tuesday’s ruling, the 2nd Circuit’s lenient test for SEC asset freezes is based on language in federal securities laws that grants the agency authority to seek injunctions “in its discretion.”
But the 3rd Circuit said the 2nd Circuit had overread the statutes by assuming Congress intended to relax the traditional preliminary injunction test, even though Congress did not expressly say that. The appeals court cited the U.S. Supreme Court’s ruling last month in Starbucks Corporation v. McKinney, which held that the National Labor Relations Board must meet the traditional standards for a preliminary injunction despite statutory language giving the agency authority to seek injunctions to preserve the status quo during its investigations.
Obviously, requiring federal agencies to meet the same standard as everyone else to obtain a preliminary injunction is not as consequential as ending Chevron deference or setting doctrinal limits on agencies’ ability to expand their power beyond explicit Congressional authorization.
But the 3rd Circuit’s new ruling is one more piece of evidence that the heyday of federal agencies is ending.
Read more:
US Supreme Court backs Starbucks over fired pro-union workers
US Supreme Court curbs federal agency powers, overturning 1984 precedent
U.S. Supreme Court just gave federal agencies a big reason to worry
(Reporting By Alison Frankel)
</body></html>Các tài sản liên quan
Tin mới
Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.
Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.
Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.